Future Wound Management: More Equipment, Biotech; Less Lowtech

The history of wound management has been dominated by a simple premise of getting wounds closed, keeping them covered and letting the body heal itself.  But the demand to accelerate the wound healing process, especially for a growing caseload of chronic wounds (driven by increased diabetes prevalence, aging population, and others) is driving a shift way from a passive role in wound management to one where materials are used to draw away exudate, kill bacteria, and maintain healing-optimized moisture levels; equipment is used to also remove exudate and otherwise stimulate the healing process; natural and bioengineered grafts are used to intervene for extreme wound types; growth factors and other biologicals are used to supplement the natural cascade of wound healing.  In short, wound healing is moved from being eminently passive to decidedly active, with considerably more medtech and biotech, with less “low-tech” (e.g., simple bandages and dressings).

The resulting balance of the overall wound care market distributed across multiple product and technology types will represent markedly different pictures between now and the next decade.

Below is illustrated the shift in wound care technologies, from a percentage of total basis and absolute share of product revenues basis:


Source: MedMarket Diligence Report #S249, “Wound Management, Worldwide Market and Forecast to 2021: Established and Emerging Products, Technologies and Markets in the Americas, Europe, Asia/Pacific and Rest of World.”  Published March 2013.


Source: MedMarket Diligence Report #S249



Leave a Reply